Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 3Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

NIH 4INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2CNS 1

Conditions

Choriocarcinoma 2Trophoblastic Tumor, Placental Site 1Ovarian Neoplasms 1Glioblastoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × carotuximab × Clear all
NCT02664961 2019-07-23

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Tracon Pharmaceuticals Inc.

Phase 2 Terminated
3 enrolled 11 charts
Gynecologic

Choriocarcinoma, Trophoblastic Tumor, Placental Site, Gestational Trophoblastic Disease

NCT01564914 2019-06-12

105GM201

Tracon Pharmaceuticals Inc.

Phase 2 Completed
22 enrolled 11 charts
CNS

Glioblastoma

NCT02396511 2019-06-11

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Tracon Pharmaceuticals Inc.

Phase 2 Completed
2 enrolled 10 charts

Choriocarcinoma

NCT01381861 2019-03-05

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Tracon Pharmaceuticals Inc.

Phase 2 Completed
23 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡